1 - 5 May 2017 Join us at the 13th annual PEGS Boston!

Going to PEGS Boston? Drop by booth #326 where we will be showcasing mirrorball

Venue: Seaport World Trade Center, Boston, MA, USA
Date: 1 – 5  May 2017
Booth: #326

We would like to invite you to the following workshop:
Title: High-Throughput Screening for Antibody Discovery Using mirrorball
Presenter: Christyne J. Kane, Senior Scientist, AbbVie Bioresearch Center, Inc.
Abstract:
The antibody discovery industry has begun to set aside traditional assay formats such as ELISA or flow cytometry in favor of more sensitive, high-throughput technologies to screen for novel biologic candidates. This presentation will highlight a selection of multiplex assays for the screening of hybridoma supernatants enabling the discovery process.

Meet mirrorball

TTP Labtech’s mirrorball high sensitivity fluorescence cytometer is a highly versatile instrument that brings process efficiencies to multiple stages in the biologics screening pipeline – from early screening and hit identification, through to characterisation and phenotypic cellular responses.

Key applications include:

  • biologics screening:
    – hybridoma, phage display, B-cell cloning, antibody fragments, peptides, scFv, Fab
  • binding characterisation:
    – Bmaxand Kd determination
  • functional assays:
    – cell health, cell cycle, proliferation, cell signalling
  • quantification of soluble proteins:
    – cytokines, hormones, growth factors

do more antibody screening with less

mirrorball represents a complete biologics screening solution. It offers analysis of bead-bound soluble antigens and cell-surface antigens expressed on both adherent and suspension cell lines in microplates. It is compatible both with washed and no-wash assay formats.

mirrorball’s multiplexing capabilities enable hit determination in high density microplates while simultaneously screening out non-specific and non-selective hits in the same well. This means antibody engineering researchers can identify cross-reactivity and selectivity but – significantly – without the loss of throughput.

Key benefits:

  • a streamlined no-wash assay format
  • unprecedented levels of throughput
  • maintaining cell morphology through in situ analysis of adherent cells
  • investigate multiple targets in one well
  • more stringent results by screening out non-specific and non-selective hits in the same sample
  • assay miniaturisation using high density microplates
  • visual confirmation of your results using an image for QC

Our team can also discuss with you our instruments used for:

  • flexible sample management workflows from ambient to -80°C (comPOUND, arktic, lab2lab)
  • unique low volume, positive displacement liquid handling for any liquid including cells or beads (mosquito, dragonfly).

Want to find out more? We offer a full range of resources, read our application notes and posters here…

application notes:

posters:

For more information about the PEGS Boston visit their website here.

banner_PEGS_2017

blog: Introducing our poster award winner

Poster Award winner: Carlos Perez Arques

In our previous blog we learned about Ana Isabel Matos (travel grant recipient) and her research aimsPicture_Carlos_Perez_Arques. This week, we’re going to speak with Carlos Perez Arques (poster award winner) to find out more about his journey into scientific discovery!

Please tell us which conference you would like your poster to appear at:
29th Fungal Genetics Conference in Asilomar Conference Center, Pacific Grove, California (USA)

Please tell us about your research:
I began my research in connection with a research project about Mucor circinelloides, an early-diverging fungus which is a causal agent for an infectious disease known as mucormycosis. Despite the existence of a modern arsenal of antifungal drugs, mortality rates for this infectious disease remain devastatingly high since Mucorales present an unusual drug resistance. Consequently, a current demand of novel therapeutic targets is triggering the exploration of the genetic basis involved in mucormycosis.
This project attempts to link gene silencing via RNAi, a fascinating mechanism which among other functions controls gene expression in this fungus, with regulating pathogenesis. My work analyzes Mucor gene silencing mechanism role in regulating essential biological processes. To do so, we are undertaking transcriptomical analyses in mutants for the RNAi pathway, which are a virulent, and comparing them to virulent wild-type strains in order to find differentially expressed genes and small RNA producing loci. So far we have determined that Mucor controls the expression of genes implicated in vegetative development, specifically in asexual sporulation and nutritional starvation responses; sexual interaction and mating; and, more importantly, virulence factors.
Furthermore, we have uncovered a new protein, named R3B2, architecture domain highly consistent with a ribonuclease. This putative ribonuclease, along with RNA-dependent RNA polymerases, takes part in an alternative or non-canonical gene silencing mechanism. By creating a knockout mutant, we have demonstrated that R3B2 is involved in pathogenesis, indicating that this non-canonical RNAi pathway, and its target genes, could be used as therapeutic targets for novel antifungal drugs.

How does your research apply to the topics of discussion at the above-mentioned conference?
The 29th Fungal Genetics Conference dedicates a fair amount of sessions to basal fungi, including Mucoralean fungi. This group of early-diverging fungi are often reluctant to classical genetic tools like transposable elements or gene mapping, so novel strategies by which to study this fungal group are always well received. My research makes use of a transcriptomic advances to understand the molecular basis of pathogenesis and virulence in an understudied organism such as Mucor circinelloides, so this approach could be extremely interesting to the conference attendants.

Mucormycosis is very little understood, owing to a lack of genetic studies related to virulence. My work tries to link a very specific non-caninocal gene silencing pathway, not present in mammals, with pathogenesis and thus establishing the foundations to create novel and effective antifungal therapies.

What do you hope to learn/gain from submitting your poster at this conference?
I started my Master’s thesis in connection with a research project about Mucor circinelloides pathogenesis, a filamentous fungi belonging to the order Mucorales which is a causal agent for an infectious disease known as mucormycosis. This work taught me RNA manipulation and detection techniques to study gene expression, hence allowing me to embark on a PhD thesis to analyze Mucor gene silencing mechanism role in essential biological processes, such as vegetative development, sexual interaction and pathogenesis. It is my first year as a PhD student and I feel the need to enlarge and improve my contact network. Attending to this conference is an excellent choice due to its international recognition and affinity with my field of study. This could allow me to carefully plan future stays on different research groups and expand my studies. Furthermore, assisting to this conference will provide an extraordinary opportunity to learn new genetic and molecular techniques which I could use in my current research, and be aware of recent findings with which to draw new hypothesis and interpretations for my results. I also believe that presenting my results in a comprehensible manner could help me grow professionally as a scientist, and I am eager to do so among an audience that shares my enthusiasm for fungal genetics.
However, political and economic turmoil in my country due to unfruitful government elections has caused a dire lack of funds in my research group. We have been almost a year without national government and because of that our group has not received all allocated funds established for our research projects. This lack of funding is threatening our ability to finance our attendance to the 29th Fungal Genetics Conference at Asilomar and urged us to request this poster award.

Well we are absolutely thrilled to be able to help to support Carlos in his endeavours!

We would like to thank Carlos, Ana and all of the tremendous applicants for sharing their research with us. Please continue to follow us on social media for updates pertaining to future travel grants or poster awards. Meanwhile, have a lovely week!

blog: When you couldn’t possibly choose the best one!

Travel Grant and Poster Award Winners!

At TTP Labtech, we are committed to aiding in the advancement of scientific discovery. As such, we recently launched two award programs. The first being a £500 travel grant, and the second, a £250 poster award. What an amazing response we had!

We received some really fantastic abstracts from researchers all over the world. Reading through them, I was really impressed with the level of detail some of the applicants went into. There really is a lot of great work happening. Luckily, picking the winner was done by random selection and I didn’t actually have to pick the best one. I don’t think I could have chosen with so many wonderful submissions!

So what were the most commonly mentioned research terms in these submissions?

Here’s a Wordle to help us analyse the response data, as you can see, cells are certainly a hot topic, with cancer studies coming in a close second!

wordleSo who are our lucky winners this time?

We are absolutely thrilled to announce our first two winners and share their submissions with you. Congratulations to Ana Isabel Matos, winner of the travel award, and Carlos Perez Arques, winner of the poster award!

Join us next week when we’ll share their research aims with you!

 

blog: addressing drug discovery bottlenecks

drug discovery bottlenecks – could these be a thing of the past?

Low-volume pipetting has become standard practice for many high-throughput screening (HTS) techniques but there are often issues with the accuracy, reliability and repeatability of bulk dispensing of reagents and samples into high density plate formats used in HTS.

In fact, a bulk reagent dispenser survey calculated that about 10% of all bulk dispensing time/work was disrupted due to instrument failure or dispensing problems [1]. Of these, tip clogging, high dead volume and soaring maintenance costs were rated the most problematic aspects of such dispensers.

Another common bottleneck is in the transition of assays from development in to HTS, with a common complaint being that different plate density and liquid handling techniques have to be used for the two processes.  This is due to the complex combination of variables that need to be assessed as part of the assay development process, and the limitation of automated liquid handling to carry out such tasks; combined with the need for high density (typically 1,536) well plate formats and a reliance on automation for the HTS process.  This miss-match results in a lot of time and effort being invested in ‘converting’ assays from one process to the other/ to ensure they run reliably in HTS. What if the same technology that provides highly accurate and precise low-volume liquid handling in assay development were to be used in high speed bulk dispensing in HTS?

Well, your dreams have come true! TTP Labtech have recently announced their new dragonfly® discovery liquid handler.  The new platform enables rapid and reliable low volume (200 nL upwards), non-contact dispensing from a positive displacement disposable pipette with 96, 384 & 1,536 well compatibility, to allow assays to be developed directly in high density plate formats. The same platform can also perform assay validation and subsequent HTS, which simplifies and aids in a smooth transition in to a high throughput environment.

dragonfly discovery has 10 channels which can be used independently with any liquid type, irrespective of viscosity. The unique combination of positive displacement, disposable tips and non-contact dispensing ensure dead volumes are minimised, and that issues of  tip clogging and cross-contamination are removed, all of which improve the efficiency and robustness of the screening process.

In addition, new software capabilities and DoE interface support the design, development and ability to run complex assays on a standalone instrumnet; thus enabling a simple, swift, user friendly set-up prior to a run.

In summary, it is now possible to use the same technology at all stages of the drug discovery process, easing assay transition, improving assay robustness, whilst remaining cost effective.

The smooth running of drug discovery processes will be featured at the following events:

At SLAS 2017, Washington, DC, USA (Feb 4-8th) TTP Labtech will be presenting a poster describing a high-throughput phenotypic screening workflow for cytoxicity determination using its comPOUND store to rapidly cherry pick individual compounds, dragonfly® discovery for rapid reagent dispensing into 1,536 well plates, and acumen Cellista for reporting medium content data from multiplexed phenotypic screening assays. In this process, dragonfly discovery rapidly dispenses many liquid types (including cells and beads) into a 1,536 well plate with no cross contamination, and minimal intervention.

[1]Comley, J. Bulk Reagent Dispensers: ubiquitous liquid handling tool for microplate filling. DDW Fall 2010

TTP Labtech will be presenting live demos of dragonfly® discovery at booth #1105 at SLAS 2017 along with presenting at ‘Late Night with LRIG – Rapid-Fire Innovation Session’, 6-8pm, Monday 6th February, and will be hosting a workshop on Tuesday 7th February, room: 143b at 2pm. Space is limited, so reserve your place at the workshop here.

press release: TTP Labtech introduces dragonfly discovery

New liquid handling platform to reduce assay development time and improve assay robustness in high throughput screening… meet dragonfly® discovery!

DF2_Top_page_PR_Banner

TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has announced the commercial premiere of its dragonfly discovery liquid handling technology at SLAS2017, in Washington, DC, USA.

Building on the success of the first dragonfly liquid handling platform, dragonfly crystal, which was designed for crystallographers, TTP Labtech has developed a second generation of the dragonfly technology. The new dragonfly discovery is poised to address the complexities of assay development, and challenges associated with validating and subsequent transferring of those assays into high throughput screening (HTS), which are well known bottle necks in the drug discovery process. This novel, user-friendly, low-volume liquid handling technology significantly reduces assay development time and greatly improves assay robustness in screening. The dragonfly discovery provides scientists with a standard platform whereby they can easily develop complex assays and screen those assays in a robust and cost efficient manner.

The new platform enables rapid and reliable low volume (200 nL upwards) dispensing from a positive displacement disposable pipette (with 4 mL capacity), and 96-, 384- & 1536-well compatibility, to allow assays to be developed directly in high density plate format using a common liquid handling platform. The same platform can also perform assay validation and subsequent HTS, which simplifies the process of assay development and aids a smooth transition in to a high throughput environment. In addition, a new software capability and user interface support the design and development of complex assays.

Joby Jenkins, director – product strategy, TTP Labtech, commented: “In the development of dragonfly discovery, our aim was to redefine reagent dispensing. Positive displacement pipetting is well known to be agnostic of liquid class and offer exceptional reliability, but it has never before been used for non-contact bulk reagent dispensing. This, combined with the fact the tips are disposable, results in an extremely accurate and reliable dispense technology, which is something the industry has been crying out for.”

TTP Labtech will be presenting live demos of dragonfly discovery at booth #1105 at SLAS2017, Washington, DC, USA, 4 Feb – 8 Feb 2017. The company will also be presenting during the ‘Late Night with LRIG – Rapid-Fire Innovation Session’ at the conference, 18:00 – 20:00, Monday, 6 Feb 2017, and will be hosting a workshop on Tuesday, 7 Feb 2017,  room: 143b at 2pm. To reserve your space for the workshop visit here.

blog: New drugs need bold approaches

Turning the screening scenario on its head

The pharmaceutical industry is under immense pressure to find better ways to bring new drugs to market, given the dwindling pipeline and the astronomical cost of late-stage failures. So, is the screening pool from which we select compounds just too small, or not chemically diverse enough?

Screening library subsets is designed to capture all the areas of the chemical space within a company’s full compound library, but by screening a much smaller number of compounds to allow the use of more complex phenotypic assays that provide data closer to the in vivo goal.

“However,” says TTP Labtech’s Dr Paul Wylie, “I believe that this approach is flawed as the subsets are selected on target-based information. Using data from historic target-based screens to select subsets for phenotypic screens runs the risk of missing good quality hits – or selecting poor compounds for next stage interrogation. Just because a compound is in a similar chemical space to another molecule, doesn’t necessarily mean that it will exert the same phenotypic response, in vivo.”

A good example is the catecholamines: dopamine, noradrenalin and adrenaline.  Whilst they only differ by the addition of a single functional group, they exert very different physiological responses (see table 3).

structure function
dopamine  mirrorball_blog_dopamine_Dec16 Inside the brain, dopamine plays important roles in motor control, motivation, cognitive control, reinforcement, and reward, as well as a number of basic lower-level functions including lactation, and nausea.
noradrenaline  mirrorball_blog_noradrenaline_Dec16 Medically it is used in those with severe hypotension. It does this by increasing vascular tone (tension of vascular smooth muscle) through α-adrenergic receptor activation.
adrenaline  mirrorball_blog_adrenaline_Dec16 As a medication it is used for a number of conditions including: anaphylaxis, cardiac arrest, and superficial bleeding. Maybe used for asthma when other treatments are not effective. Inhaled epinephrine maybe be used to improve the symptoms of croup.

Table 3.

“In my view,” says Dr Wylie, “it is time to turn the screening scenario on its head. Screening is about excluding the compounds that are not useful; so, instead of screening in a target-based way first, then using a phenotypic response to backup the data, we should screen phenotypically and follow up with target-based identification.”

What would be the requirements to successfully implement phenotypic screening at primary throughputs? “Target-based screening was adopted partly because it was easy to automate, fast, reproducible and relatively inexpensive to run on very large compound sets”, he explains. So, just how far off running a full deck phenotypic screen are we?

We would need:

  1. Automation to run assays in 1536-well plates, to achieve the required throughput. Many liquid handling systems are now able to do this very effectively.
  2. Manageable cell costs/cell numbers. Primary cells and iPS cell lines are more physiologically relevant but incur higher costs. HTS requires the use of around 100 cells per 1536-well plate to make these cost-effective.
  3. Consistent, fast scan and analysis times to fit into a fully automated HTS process. This is important because many HCA instruments have variable read times.
  4. Manageable data files from 2-3 million wells.
  5. Straightforward biology.

Dr Wylie believes that throughput and assay complexity are perceived to be the main barriers to running a full deck phenotypic HTS, but, he asks, “Is that really true?”

  • The biology itself can be limiting, but only in certain projects. Phenotypic screening is robust. “Many phenotypic assays look at quite basic readouts: cell viability (live dead/apoptosis), reporter gene expression, cell cycle, angiogenesis formation. These are simple assays to screen,” he points out.
  • For throughput: “it is true that many typical imaging systems do not fulfill the criteria for a HTS manager to run in a full-deck screen. So it is best not to use a standard microscope-based imaging system”, he concludes.

Laser-scanning imaging cytometers (LSICs), such as acumen Cellista (TTP Labtech), combine object recognition with bulk read speeds (typically under 5 minutes per 1536-well plate). It requires fewer cells (typically 100/well). It also produces very small file sizes, so the IT requirements are the same as for target-based screening. These features mean that LSICs like acumen Cellista are ideally placed to remove the compromises and offer practical high throughput, full deck phenotypic screening.

“The costs of phenotypic primary screens are higher than traditional target-based screening; but it is surely much cheaper than pursuing poor compounds which fail at later stage drug development,” explains Dr Wylie.

“I believe the only barrier to running full deck phenotypic screening today is the willingness and belief to accept it as a key area of drug screening and then to implement it.”

news: Affordable automation for protein crystallographers – the ultimate lab bundle for 2017

Affordable automation for protein crystallographers – the ultimate lab bundle for 2017

Starting in 2017, our lab bundle pack is designed to automate your crystallisation drop setting and optimisation whilst meeting increasingly demanding budgets. With over 300 academic publications in 2 years referencing mosquito, we know how important it is to provide you with productivity and peace of mind in your daily research. Utilising the superior positive displacement technology of TTP Labtech’s mosquito and dragonfly, you can benefit from unrivalled accuracy and repeatability of across a wide range of viscosities, combined with effortless, intuitive software accessible to even the most novice user.

  • 3 protein crystallisation instruments
  • 2 year full warranty
  • 1 unlimited software licences

>>Get your lab bundle

The lab bundle pack includes:

  • mosquito® Crystal (2-way) & dragonfly® (5-head) & MXone
  • consumables pack for mosquito & dragonfly
  • extended 2-year guarantee including a product maintenance visit
  • unlimited software licences

TTP Labtech’s mosquito & dragonfly delivers:

  • unrivalled accuracy and repeatability at nanolitre volume using our unique true-positive displacement technology
  • versatile workflows to miniaturise and automate processes to save time and precious crystals
  • robust and very easy to use, suitable multi-user labs
  • proven track record of research success by 300+ publications in 2 years

>>Get your lab bundle

ask the expert link

 

 

 

blog: Screening methodologies

Counting compounds in or out?

In the search for new drugs, the harvest of low hanging fruit and increased regulatory hurdles have decreased R&D productivity. Many candidates incur enormous financial losses by failing very late in clinical trials. But this failure is due to safety/toxicity concerns as opposed to lack of efficacy. So, are we using the best methods to select our hit compounds?

Target-based high-throughput screening 

In the 1990s, companies turned to target-based primary screening to screen more compounds in a reliable manner. Target-based screening typically uses overexpressing proteins identified as having a key role in the disease area to make a consistent, sensitive model. The assays are robust biochemical ones that are easily automated to run in high throughput, as a pharmaceutical compound library is now around 2-3 million compounds. However, once hit compounds are identified, their effects then need to be checked in a biological system.

Target-based screening has generated many ‘hits’, but there has been a greater failure in the clinic due to poor target validation early on in the drug discovery process. The main cost in drug discovery is not the initial high throughput screen; it is the stages after that.

“People often talk about screening as finding ‘hit’ compounds. Paradoxically, in my opinion, it is about screening out the compounds that are no good – so they aren’t pursued and money is not wasted in the later stages of drug discovery” say Dr Paul Wylie, TTP Labtech’s Head of Applications.

Phenotypic Screening: gaining physiological relevance

There is now a renewed interest in phenotypic screening as a discovery tool. “The real benefit”, says Dr Wylie, “is seeing what each compound actually does to a cell; not just to an isolated protein in a non-physiological environment.”

High Content Screening (HCS) is a standard automated approach to look at phenotypic changes within the cell in response to a compound. Normally, multiple features of each individual cell or organism present are measured. It is this that underpins the approach’s true power.

“HCS enables phenotypic assays that can measure changes within a cell, or movement between cells, or permit the analysis of specific sub-populations of cells in a heterogeneous mix, that would be difficult or impossible to perform with other technologies,” explains Dr Wylie.

“High content assays are amongst the most demanding assays to run on a large scale since they involve using live cells, multiplexing of fluorescent dyes/proteins or probes and have multiple readouts,” he continues.

The vast majority of HCS readers are based on automated microscopy. “Initially, these techniques, whilst powerful, were difficult to use, relatively slow and presented barriers to a mass uptake within pharma” says Dr Wylie. “Over the last 15 years, many of the issues have been addressed and, today, they are used in mainstream R&D for phenotypic screening, which is smaller scale”.

The reasons for not using them in primary screening are:

  • microscope-based high content imaging systems are relatively slow compared to target-based screening methods
  • they are generally incompatible with high density (1536-well) microplates
  • they generate large data sets

“Sophisticated IT storage systems are available to archive these large amounts of data”, says Dr Wylie, “but the IT infrastructure to handle the data effectively and – crucially – retrieval of the data can still be a pain point.”

Another problem is that modern screens have focussed on more physiologically-relevant cell lines, which now include primary cell lines and induced pluripotent stem cells (iPS). “These cells are ever closer to a true in vivo model, but the numbers normally required to run a phenotypic screen can make the cost prohibitive,” explains Dr Wylie.

Is primary screening afraid of phenotypic assays?

“With the availability of significant improvements in assay reagents, labware and readers, I believe it is now possible to run a cost-effective, robust approach to screening entire compound libraries in a phenotypic manner,” says Dr Wylie.

Laser-scanning imaging cytometers (LSICs), such as acumen Cellista (TTP Labtech), combine object recognition with bulk read speeds (typically under 5 minutes per plate). It requires far fewer cells (typically 100/well). It also produces very small file sizes, so the IT requirements are the same as for target-based screening. This means that LSICs like acumen Cellista are ideally placed to offer practical high throughput, full deck phenotypic screening.

“The costs, it is true, are higher than traditional target-based screening approaches;” states Dr Wylie, “but it is surely a much cheaper way forward than pursuing poor compounds that ultimately fail at later stage drug development. Screening is about excluding the compounds that are not useful, not necessarily about finding the hits.”

blog: Let’s talk crystallography in Asia and Oceania

Let’s talk crystallography in Asia and Oceania.

Hanoi, Vietnam will become ‘The city of crystallography’ from 3 – 7th December, hosting the 14th conference of the Asian Crystallography Association (AsCA 2016) and
TTP Labtech’s protein crystallography open workshop.

This region has a long and distinguished history in the field of crystallography:

  • Bragg’s Law, formulated by the Australian Lawrence Bragg
  • seminal contributions to the crystal engineering of organic molecules (India)
  • coordination polymers (Australia, Japan, Hong Kong and China).

This is highlighted in a recent themed issue of a Royal Society of Chemistry journal celebrating Crystallography in the Asia-Pacific region (CrystEngComm (2014) 16: 6276). This region is also one of the youngest and the fastest growing of the four Regional Associates of the International Union of Crystallography (IUCr).

If you are going to AsCA 2016 and would like to join us for a relaxing afternoon of talks by leading crystallographers in both industry and academia and meet other users of
TTP Labtech’s liquid handling instruments, please come along on Saturday 3rd Dec at 11am at Hotel Mövenpick, 83 Lý Thường Kiệt, Cửa Nam, Hoàn Kiếm, Hà Nội. Following the talks and discussions, you will be able to delight in the tasty traditional Vietnamese cuisine following a Hanoi sightseeing. At this open workshop you will have the chance to learn more about best practices and successful strategies to crystallise proteins using
TTP Labtech’s range of mosquito® and dragonfly® liquid handlers. This is a FREE event, but places are limited so please sign up to avoid disappointment.

The following speakers at the workshop will also be available for informal discussions during the day:

Dr. Andrew Doré “Extra-helical binding site of a Glucagon Receptor antagonist: problems and solutions using the mosquito LCP”

Dr. Andrew Doré is Director of Crystallography at Heptares Therapeutics, UK. His work addresses some of the hurdles associated with the instability of GPCRs and aims to generate small molecules and therapeutic antibodies targeting challenging or previously undruggable GPCRs.

Prof. Kurt Krause “Simplified Method for Influenza Neuraminidase Purification for Structural Studies”

Prof. Kurt Krause is Director of the Webster Centre for Infectious Diseases and a Professor of Biochemistry at the University of Otago. His group focus on the structural biology of infectious diseases.

Dr. S. Ramaswamy is an Senior Professor at Institute for Stem Cell Biology and Regenerative Medicine, India. His research interests lay in the area of protein-protein interaction networks of translocation pathways and lipid signaling. His general research question is ‘what could be the differences in the modulation and dynamics of protein complexes/ lipids between normal cells and cell under the stress?’

If you would like to find out more about the mosquito range of liquid handlers or dragonfly please contact our experts at crystallography@ttplabtech.com.

 

 

18 Oct - 22 Oct 2016 ASHG 2016 recap

Thanks to everyone who spoke with us at ASHG 2016!

In case you missed it, you can find a full recap!

mosquito liquid handlers for genomics

features:

  • superior accuracy and precision coupled with high speed transfers using true positive displacement pipetting technology
  • reduce sample and reagent requirements to 20 pg or less of nucleic acid and up to 50-fold reduction in reagents
  • no cross-contamination, no carryover with our low-cost disposable pipettes
  • be in control with the simple software interface by easily creating new protocol

application areas

low volume liquid handling with mosquito HTS, HV and X1

  • synthetic & molecular biology: High-throughput, miniaturised reactions for PCR, cloning and DNA assembly with mosquito
  • nucleic acid sequencing: Low cost, low volume library preparation for single cell analysis, including DNAseq, RNAseq and normalisation
  • gene expression profiling: Cost-effective, high-throughput analysis of mRNA with rapid qPCR set-up

Poster title: Automated, low-cost, miniaturized RNA-Seq and DNAseq library preps

>>Get our latest app note here: This application note presents a high-throughput, miniaturised workflow, in which differentiated pancreatic stems cells were studied using single-cell RNA-Seq (scRNA-Seq), in Dr. Louise Laurent’s lab at University of California, San Diego, USA.

>>Watch our free on-demand tutorial here: Low-volume, automated single cell RNA-seq library preparation

>>Read the latest JALA publication here: Miniaturization Technologies for Efficient Single-Cell Library Preparation for Next-Generation Sequencing

Are you interested in a demo? >>Book it here!

24 - 25 April 2017 Join us at the 10th annual Proteins and Antibodies Congress!

See mirrorball at this year’s Proteins and Antibodies Congress!

Venue: Novotel London West, Hammersmith International Centre, London, UK
Date: 24-25 May 2017
Booth: #6

TTP Labtech’s mirrorball high sensitivity fluorescence cytometer is a highly versatile instrument that brings process efficiencies to multiple stages in the biologics screening pipeline – from early screening and hit identification, through to characterisation and phenotypic cellular responses.

Key applications include:

  • biologics screening:
    – hybridoma, phage display, B-cell cloning, antibody fragments, peptides, scFv, Fab
  • binding characterisation:
    – Bmaxand Kd determination
  • functional assays:
    – cell health, cell cycle, proliferation, cell signalling
  • quantification of soluble proteins:
    – cytokines, hormones, growth factors

do more antibody screening with less

mirrorball represents a complete biologics screening solution. It offers analysis of bead-bound soluble antigens and cell-surface antigens expressed on both adherent and suspension cell lines in microplates. It is compatible both with washed and no-wash assay formats.

mirrorball’s multiplexing capabilities enable hit determination in high density microplates while simultaneously screening out non-specific and non-selective hits in the same well. This means antibody engineering researchers can identify cross-reactivity and selectivity but – significantly – without the loss of throughput.

Key benefits:

  • a streamlined no-wash assay format
  • unprecedented levels of throughput
  • maintaining cell morphology through in situ analysis of adherent cells
  • investigate multiple targets in one well
  • more stringent results by screening out non-specific and non-selective hits in the same sample
  • assay miniaturisation using high density microplates
  • visual confirmation of your results using an image for QC

Our team can also discuss with you our instruments used for:

  • flexible sample management workflows from ambient to -80°C (comPOUND, arktic, lab2lab)
  • unique low volume, positive displacement liquid handling for any liquid including cells or beads (mosquito, dragonfly).

Want to find out more? We offer a full range of resources, read our application notes and posters here…

application notes:

posters:

For more information about the 10th Annual Proteins & Antibodies Congress visit their website here.

10thproteinsandantibodiescongress

8 May 2017 Join us at the Norwich Single Cell Symposium 2017!

Join us at the Norwich Single Cell Symposium 2017!

Venue: Earlham Institute, Norwich, UK
Date: 8th May 2017

Join us for a day of talks and discussion on the development and application of new technologies to decode life at the single cell level and discover how our range of mosquito® liquid handlers can advance your research!

TTP Labtech’s mosquito is an essential tool for miniaturising reaction volumes by up to 90% for a wide range of genomics workflows. Read the scientific studies using the mosquito HTS to discover how this resulted in higher throughput and greater statistical power.

Benefit from:

  • accuracy and precision with nanolitre to microlitre volumes
  • accurately handle any liquids with high viscosity, such as enzymes in glycerol or genomic DNA
  • no-cross-contamination or carryover
  • future-proof open platform

Learn more from these peer reviewed articles:

>> Discover the mosquito liquid handlers for accurate, miniaturised genomics workflows

For more information, visit the Norwich Single Cell Symposium website here

 

 

 

 

 

 

Blog: How to seamlessly grow your library to a million compounds in three easy steps

How to seamlessly grow your library to a million compounds in three easy steps

Automated solutions to improve the ‘flow’ in the sample management workflow and reduce costs

As reported in a recent survey, the top three requirements for a successful compound management system include: accessibility, the ability to maintain a dynamic collection, and compound integrity. Although it is obvious that compound management groups need to consider all these things, there is also mounting pressure to reduce costs while still retaining integrity and efficiency, which creates a challenging and complex task for compound management.

Intelligent sample management: moving compounds seamlessly – a case study from Dart NeuroScience (San Diego, USA)

Dart NeuroScience LLC (DNS) is a leading pharmaceutical company focusing on the discovery and development of innovative drugs for memory disorders. DNS made the radical decision to create more drug compounds in-house thereby protecting their own IP. To succeed in this task which would increase the size of their compound collection to 1 million compounds, many challenges would need to be overcome.

TTP Labtech Ltd. (Melbourne, UK) embraced the challenge and successfully supplied DNS with all the technology and tools to optimise their workflow in 3 easy steps:

1. Storing their compounds in high-density, automated stores

Currently, DNS possess 6 automated comPOUND freezers (TTP Labtech) that can store 1.2 million compounds. The stores are linked to increase throughput as samples held in several freezers can be simultaneously retrieved into one 96-well format rack.

2. Processing the tubes using automated retrieval and transport system

No more manual processing of tubes from store to aliquoting and then back to store. DNS is now able to process 30,000 tubes per day using TTP Labtech’s comPILER sample processing system.  The pick-time was reduced by 9-fold per 96-well plate with a saving of 1.5 FTEs.

3. Automating the creation of assay ready plates

DNS has decreased the total picking time for a 5,000 hit-picking campaign by 80% and the total personnel time required by 88%. In addition, these improvements have enabled assays to be miniaturised down to nanolitre volumes in 1536-well plates.

Dr Jose Quiroz (Associate Director at DNS) remarked, “There are three main reasons why we chose TTP Labtech as our preferred vendor: 1) The products – they had the products that did exactly what we needed them to do; 2) cost – because comPOUND is a modular system the upfront cost is reduced, but we still have the capability to expand; 3) the people – we have great trust in TTP Labtech, they have always been there when we have needed them and the service engineers go an extra mile to help customers anytime.”

Click here if you would like to read the DNS case study

You can also meet our sample management expert and learn about our streamlined tube-to-plate processing solution at the following events:

 

If you have any other questions or want to talk to a TTP Labtech expert about your sample management workflow requirement please contact discover@ttplabtech.com.

09 May - 12 May 2017 Discover effective biobanking at ISBER 2017!

Discover effective biobanking at ISBER 2017!

Venue:   Toronto, Canada
Date:       09 May -12 May 2017
Booth:   #30

Snapshot presentation by Paul Lomax: Counting the Costs: The True Price of Manual and Automated Cold Storage

This year ISBER’s Annual Meeting theme is Due North: Aligning Biobanking Practice with Evolving Evidence and Innovation.

Effective design and management of compound collections is crucial to the success of research efforts in the Pharmaceutical, Biotechnology and Agri-Science industries. In addition, academic organisations are establishing comprehensive compound management infrastructures to help realise their target validation and drug discovery goals.

TTP Labtech’s unique pneumatic technology uses a cushion of compressed air or nitrogen and a system of flexible tubes to transport microtubes. This makes our instrumentation extremely reliable and robust compared to traditional systems that use robots. Our modular stores, comPOUND® and arktic®, also minimise the use of moving parts that can malfunction in refrigerated conditions and our proven technology ensures that users will have maximum uptime and availability of their systems.

Downstream automation platforms such as our range of mosquito® liquid handlers can be used more efficiently by delivering samples to specific SBS rack locations, thereby avoiding the need for additional re-arraying steps.

Visit our booth and speak to our experts about how comPOUND® and arktic® can future proof your collection.

Or download our new Dart NeuroScience LLC (DNS; San Diego, CA) case study:
comPOUND: intelligent management – moving compounds seamlessly

For more information about the ISBER 2017 Annual Meeting (09-12 May), click here

ISBER 2017 logo

 

4 Apr - 6 Apr 2017 Advance your genomics research at SynBioBeta 2017!

Advance your genomics research at SynBioBeta 2017!

Venue: Imperial College London, UK
Date: 4 – 6 April 2017

The focus of this year’s conference is to connect the global synthetic biology community by fostering the dialogue between entrepreneurs, business executives, tech practitioners, technology scouts, academics, and investors. Join us for insightful discussions on: advancements in metabolic engineering, designer biomaterials, engineering biology for consumer products, engineering environmental sustainability in the circular economy, hardware to make biology easier to engineer, public perception on engineering biology, and if synthetic biology will be the key to our future health.

This year we will be showcasing arktic® and mosquito® HTS, HV and X1. – Watch our arktic video and find out how TTP Labtech’s innovative technology can securely store your DNA/RNA cell lines and tissues at -80°C without any freeze/thaw issues!

For more information on SynBioBeta London 2017 click here

SynBioBeta logo

 

 

 

 

25 Mar - 28 Mar 2017 See how mosquito can further your genomics research at ABRF 2017

See how mosquito can further your genomics research at ABRF 2017

Venue: Town and Country Resort & Convention Center, San Diego, CA, USA
Date: 25-28 March 2017
Booth: 526

ABRF 2017, “A Forum for Advancing Today’s Core Technologies to Enable Tomorrow’s Innovations,” will bring together international leaders in core disciplines to provide a vision of what can be done, and insights toward making further progress as we work in the present.

The TTP Labtech team will be there, showcasing mosquito® HTSHV and X1. Come and find out how we can help you accelerate your genomics research!

mosquito liquid handlers for genomics
features:

  • superior accuracy and precision coupled with high speed transfers using true positive displacement pipetting technology
  • reduce sample and reagent requirements to 20 pg or less of nucleic acid and up to 50-fold reduction in reagents
  • no cross-contamination, no carryover with our low-cost disposable pipettes
  • be in control with the simple software interface by easily creating new protocol

application areas

low volume liquid handling with mosquito HTS, HV and X1

  • synthetic & molecular biology: High-throughput, miniaturised reactions for PCR, cloning and DNA assembly with mosquito
  • nucleic acid sequencing: Low cost, low volume library preparation for single cell analysis, including DNAseq, RNAseq and normalisation
  • gene expression profiling: Cost-effective, high-throughput analysis of mRNA with rapid qPCR set-up

>>Read the latest JALA publication here: Miniaturization Technologies for Efficient Single-Cell Library Preparation for Next-Generation Sequencing

For more information about ABRF 2017 visit their website here

ABRF2017_logo

26 May - 30 May 2017 Meet mosquito and dragonfly at ACA 2017!

meet mosquito and dragonfly at ACA 2017!

Venue: New Orleans, LA, at the Hyatt Regency Hotel.
Date: 26 – 30 May 2017

Visit our booth at this year’s American Crystallographic Association meeting (ACA 2017) and speak to our experts to find out how our range of liquid handlers can help enhance your research! – Or book a demo on mosquito crystal or dragonfly!

web banner image

With mosquito crystal, you can use smaller volumes of precious protein sample with no risk of cross contamination. This results in cost savings and allows more extensive screening. You can automate all the popular protein crystallisation screening techniques – hanging drop, sitting drop and microbatch as well as seeding or additive screening plate preparation – without the need to make set-up changes to the instrument.

For more information on the American Crystallographic Association’s 2017 Meeting (26-30 May 2017) visit their website here

ACA 2017 logo

app note: eliminating false-negative hits in ATP‑luminescence